New Data Shows CK1d Blocks Tau in AD Model

RNS Number : 5620J

Proteome Sciences PLC

18 July 2013

 



Proteome Sciences plc

New Data Shows CK1d Blocks Tau in AD Model

18^th July 2013, Cobham, UK:  Proteome Sciences yesterday made two poster presentations showing new data and results from its novel casein kinase 1 delta (CK1d) inhibitor program in Alzheimer's disease.  The results show that the two lead compounds are orally available, attain therapeutic levels in the brain of experimental Alzheimer's models and improve cognitive behaviour.  When the tau protein of treated animals was analysed a decrease was seen at key sites in total tau deposition and in tau phosphorylation.  Treatment also caused a dramatic drop in the amount of the target protein in the brain.  Taken together these data show that inhibition of CK1d acts through multiple mechanisms to reduce the amount of pathological tau protein which is increasingly recognised as a major goal for effective Alzheimer's disease treatments.

Commenting on the results, Dr. Ian Pike, COO of Proteome Sciences plc and presenting author of the posters said:

"Having our posters selected for presentation at AAIC reflects the recognition and potential of our CK1d inhibitor program for treating Alzheimer's disease and other tauopathies.  The latest results provide a strong mechanistic basis for the improved cognition seen in treated animals.  As the pharmaceutical industry is increasing the search for new targets beyond beta-amyloid our ability to reduce tau pathology is very timely and will enhance our ongoing discussions to outlicense our CK1d program to the right pharmaceutical partner."

- Ends -

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Chief Executive Officer	Tel: [phone]
Dr. Ian Pike, Chief Operating Officer James Malthouse, Finance Director
Nominated Adviser
Cenkos
Stephen Keys/Camilla Hume	Tel: [phone]
Public Relations
IKON Associates
Adrian Shaw
Tel: [phone]

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag^® (TMT^®) workflows developed on the latest Orbitrap^® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT^® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com

 

END

 

 

MSCEASXXFAXDEFF